Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508259 · ClinicalTrials.gov registry record · Phase 1
University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial
A Phase 1 study of Autism Spectrum Disorders, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT02508259: Completed Phase 1 study of Autism Spectrum Disorders, sponsored by University of California, San Diego.
NCT02508259 is a Phase 1 study of Autism Spectrum Disorders that has completed, run by University of California, San Diego. The registered enrollment target is 10 participants, below the 168-participant average among 20 other Autism Spectrum Disorders trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02508259, a Phase 1 study of Autism Spectrum Disorders, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to test the safety and efficacy of a single, intravenous dose of suramin in autism spectrum disorders (ASD).
Primary Outcome
ADOS2 comparison scores are units on a scale of 0-10. A score of 7-10 was required for enrollment. A score of 7-10 is diagnostic for autism spectrum disorder (ASD). The higher the score, the more severe the core symptoms of autism spectrum disorder. Scores of 6 and below are considered off the ASD spectrum.
Conditions Studied
Interventions
- DRUG Saline
- DRUG Suramin
Study Locations (1)
California
- University of California, San Diego School of Medicine - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT02508259 record still lists
NCT02508259 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 168-participant average among 20 other Autism Spectrum Disorders trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Autism Spectrum Disorders appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT02508259 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02508259 about?
NCT02508259 is a clinical study titled "University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial". This study is designed to test the safety and efficacy of a single, intravenous dose of suramin in autism spectrum disorders (ASD).
What is the current status of trial NCT02508259?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-05. Estimated completion is 2016-04.
What conditions does trial NCT02508259 study?
This clinical trial studies the following conditions: Autism Spectrum Disorders.
What interventions are being tested in trial NCT02508259?
The interventions under investigation include: Saline (DRUG), Suramin (DRUG).
Who is sponsoring clinical trial NCT02508259?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02508259 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02508259's enrollment target sits among peer trials
10 18th of 20 higher than 2 of 20 other Autism Spectrum Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Brain Imaging Study of Adults With Autism Spectrum Disorders
COMPLETED · Phase 1
-
Water Competency Intervention in Autism
RECRUITING · NA
-
Phenotypic and Genetic Factors in Autism Spectrum Disorders
ACTIVE NOT RECRUITING
-
Project AFECT (Autism Family Empowerment Coaching and Training Program)
ACTIVE NOT RECRUITING · NA
-
Telehealth Coaching for Families of Children With Autism
COMPLETED · NA
-
Screening and Linkage to Services for Autism
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia